Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 2,901 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Insulin Clear all
Completed Phase 1 Interventional

Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes

NCT01544881
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Technosphere Insulin Inhalation Powder, Rapid Acting Analog
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 17, 2026, 7:32 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

NCT07160257
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 17, 2026, 7:32 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise

NCT07226583
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Exercise Physiology
Interventions
Standard-of-Care Guidance (SoC), Usual Care (UC), netIOB & Exercise Toolkit (NEXT), Continuous Glucose Monitoring, Continuous Ketone Monitoring
Behavioral · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.

NCT02064166
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy
Interventions
Intranasal Insulin
Drug
Lead sponsor
Peter Novak
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2018 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Vigabatrin and Insulin Sensitivity

NCT04321395
View directory record Official record
Conditions
NAFLD, Obesity
Interventions
Vigabatrin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Intranasal Insulin and Post-stroke Cognition: A Pilot Study

NCT02810392
View directory record Official record
Conditions
Stroke
Interventions
Intranasal Insulin, Intranasal saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 17, 2026, 7:32 AM EDT
Completed No phase listed Observational

Microbiome Insulin Sensitivity Study

NCT03120871
View directory record Official record
Conditions
Obesity, Insulin Resistance, Type2 Diabetes
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years to 17 Years · Female only
Enrollment
54 participants
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 17, 2026, 7:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacogenetics of Response to GLP1R Agonists

NCT05071898
View directory record Official record
Conditions
Obesity, Diabetes Type 2
Interventions
Semaglutide Pen Injector [Ozempic]
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Cranberry Extract Supplementation on Cardiovascular Risk Factors in Obese, Insulin Resistant Humans

NCT02068144
View directory record Official record
Conditions
Insulin Resistance, Atherosclerosis
Interventions
Cranberry Extract, Placebo
Dietary Supplement · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04618744
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Interventions
ORMD-0801 (Insulin) capsule 8 mg BD, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

NCT01306214
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Placebo, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 17, 2026, 7:32 AM EDT
Active, not recruiting No phase listed Observational

T1D Pregnancy & Me

NCT06959316
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Pregnancy in Diabetics, Pregnancy, High-Risk, Insulin Dependent Diabetes
Interventions
Hybrid closed loop insulin delivery system
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes

NCT02060916
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
PAZ320
Drug
Lead sponsor
Boston Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Jefferson, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Not applicable Interventional Results available

Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes

NCT00659165
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin Detemir, Insulin Glargine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Timing Estrogen After MenoPaUSe

NCT01605071
View directory record Official record
Conditions
Insulin Resistance
Interventions
Estradiol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Not applicable Interventional

Multi-Center Study Comparing Efficacy and Safety of Frequently Modified Insulin Therapy

NCT02424500
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypoglycemia
Interventions
d-Nav, Blood Glucose Monitoring System
Device
Lead sponsor
Hygieia Research LLC
Other
Eligibility
21 Years to 70 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Exenatide for Smoking Cessation and Prevention of Weight Gain

NCT05610800
View directory record Official record
Conditions
Smoking Cessation, Weight Gain
Interventions
Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 17, 2026, 7:32 AM EDT
Active, not recruiting Not applicable Interventional

Monounsaturated Fatty Acid Supplementation for Overweight and Obese Individuals With Prediabetes

NCT05560971
View directory record Official record
Conditions
PreDiabetes, Insulin Resistance, Overweight, Obesity
Interventions
Palmitoleic acid, Placebo
Dietary Supplement · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 7:32 AM EDT
Completed No phase listed Observational

Insulin Secretory Defects in Pima Indians at High Risk for NIDDM

NCT00410800
View directory record Official record
Conditions
NIDDM
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Circuit Training and Motivational Interviewing to Reduce Type 2 Diabetes in Youth

NCT00693511
View directory record Official record
Conditions
Obesity and Type 2 Diabetes
Interventions
Circuit Training, Circuit training + motivational interviewing
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
14 Years to 18 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Phase 3 Interventional

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

NCT00135941
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
insulin glargine, insulin glulisine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years to 70 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2009 · Synced Oct 17, 2026, 7:32 AM EDT
Recruiting Not applicable Interventional

Utilizing Community Health Workers as Diabetes Technology Coaches for Children With Type 1 Diabetes Using Automated Insulin Delivery

NCT07154251
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Community Health Worker
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
5 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Not applicable Interventional Results available

Prepivotal Omnipod Horizon™ Automated Glucose Control System

NCT04176731
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Omnipod Horizon™ Automated Glucose Control System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
6 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Palo Alto, California • Denver, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 17, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT03951805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 17, 2026, 7:32 AM EDT